PRINCETON, N.J.--(BUSINESS WIRE)--Cytogen Corporation (NASDAQ: CYTO) today reported outcomes data from a large cohort study demonstrating the value of PROSTASCINT® (capromab pendetide) in predicting prognosis in prostate cancer.i The study evaluated the outcomes of patients whose PROSTASCINT images showed uptake in the central abdomen, a finding suggestive of metastatic disease, as compared to those without such findings. In the study, prostate cancer-specific death rates were 10 times higher in patients with central abdominal uptake (CAU) than in patients without CAU (p=0.005).i These results further reinforce that PROSTASCINT offers a level of accuracy and detail to prostate cancer imaging that can aid clinicians in defining patients’ prognoses and treatment regimens.
